Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes

Kardiologia Polska

Volumn 67, Issue 8, 2009, Pages 827-834

  Śpiewak, Mateusz ^a,b   Małek, Łukasz A ^a   Kostrzewa, Grazyna ^b   Kisiel, Bartłomiej ^c   Serafin, Agnieszka ^b   Filipiak, Krzysztof J ^b   Płoski, Rafał ^b   Opolski, Grzegorz ^b  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Acute coronary syndromes; Antiplatelet drugs; Multidrug resistance polymorphism; Response variability

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; CLOPIDOGREL; COLLAGEN; CYTOCHROME P450 2C19; MULTIDRUG RESISTANCE PROTEIN 1; PURINERGIC P2Y12 RECEPTOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BARE METAL STENT; DEATH; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PHENOTYPE; PROGNOSIS; STATISTICAL ANALYSIS; STROKE; THROMBOCYTE FUNCTION; TREATMENT RESPONSE;

EID: 72449195234     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008; 29: 2909-2945
2. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1660 (Pubitemid 47227122)
3. Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res 2007; 120: 311-321
4. Reny JL, De Moerloose P, Dauzat M, et al. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 444-450 (Pubitemid 351280111)
5. Crescente M, Di Castelnuovo A, Iacoviello L, et al. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008; 99: 14-26.
6. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425 (Pubitemid 44522148)
7. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750 (Pubitemid 44648629)
8. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4: 542-549
9. Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49: 657-666 (Pubitemid 46205039)
10. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317 (Pubitemid 46891710)
11. Huczek Z, Filipiak KJ, Kochman J, et al. Baseline platelet reactivity in acute myocardial infarction treated with primary angioplasty - influence on myocardial reperfusion, left ventricular performance, and clinical events. Am Heart J 2007; 154: 62-70. (Pubitemid 46920475)
12. Malek LA, Spiewak M, Filipiak KJ, et al. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes. Kardiol Pol 2007; 65: 40-45 (Pubitemid 46226307)
13. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375
14. Frere C, Cuisset T, Morange PE, et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008; 101: 1088-1093
15. Giusti B, Gori AM, Marcucci R, et al. Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis 2008; 196: 341-348
16. Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res 2008; 121: 463-468 (Pubitemid 351174278)
17. Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007; 17: 1057-1064 (Pubitemid 351339490)
18. Fontana P, Hulot JS, De Moerloose P, et al. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 2007; 5: 2153-2155 (Pubitemid 47450038)
19. Cuisset T, Frere C, Quilici J, et al. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thromb Res 2007; 120: 893-899 (Pubitemid 47432706)
20. Lev EI, Patel RT, Guthikonda S, et al. Genetic polymorphisms of the platelet receptors P2Y (12), P2Y (1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 2007; 119: 355-360 (Pubitemid 44918095)
21. Bernardo E, Angiolillo DJ, Ramírez C, et al. Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease. Platelets 2006; 17: 586-590 (Pubitemid 44837729)
22. Bura A, Bachelot-Loza C, Ali FD, et al. Role of the P2Y12 gene polymorphism in platelet responsiveness to clopidogrel in healthy subjects. J Thromb Haemost 2006; 4: 2096-2097 (Pubitemid 44226807)
23. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29: 21-30.
24. Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80: 486-501.
25. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549 (Pubitemid 36159890)
26. Malek LA, Kisiel B, Spiewak M, et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 2008; 72: 1165-1169 (Pubitemid 351957086)
27. Silber S, Albertsson P, Avilés FF, et al. Guidelines for percutaneous coronary interventions. Eur Heart J 2005; 26: 804-847
28. Hayward CP, Harrison P, Cattaneo M, et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312-319
29. Foussas SG, Zairis MN, Patsourakos NG, et al. The impact of oral antiplatelet responsiveness on the long-term prognosis after coronary stenting. Am Heart J 2007; 154: 676-681 (Pubitemid 47429586)
30. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235 (Pubitemid 32721947)
31. Madan M, Berkowitz SD, Christie DJ, et al. Rapid assessment of glycoprotein IIb/IIIa blockade using the platelet function analyzer (PFA-100) during percutaneous coronary interventions. Am Heart J 2001; 141: 226-233 (Pubitemid 32128727)
32. Ye S, Dhillon S, Ke X, et al. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 2001; 29: E88-8.
33. Jamroziak K, Balcerczak E, Młynarski W, et al. Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of Polish population. Pol J Pharmacol 2002; 54: 495-500. (Pubitemid 35214975)
34. Jamroziak K, Młynarski W, Balcerczak E, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004; 72: 314-321 (Pubitemid 38520728)
35. Tan EK, Drozdzik M, Bialecka M, et al. Analysis of MDR1 haplotypes in Parkinson's disease in a white population. Neurosci Lett 2004; 372: 240-244 (Pubitemid 39470204)
36. Kurzawski M, Droździk M, Suchy J, et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol 2005; 61: 389-394 (Pubitemid 41569314)
37. Kurzawski M, Pawlik A, Górnik W, et al. Frequency of common MDR1 gene variants in a Polish population. Pharmacol Rep 2006; 58: 35-40.
38. Jamroziak K, Balcerczak E, Calka K, et al. Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk Res 2009; 33: 332-335
39. Aarnoudse AJ, Dieleman JP, Visser LE, et al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics 2008; 18: 299-305.
40. Drescher S, Schaeffeler E, Hitzl M, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002; 53: 526-534 (Pubitemid 34527155)
41. Fellay J, Marzolini C, Meaden ER, et al. Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30-36 (Pubitemid 34119193)
42. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189-199 (Pubitemid 32777772)
43. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478 (Pubitemid 30183327)
44. Heestermans AA, van Werkum JW, Taubert D, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 2008; 122: 776-781